Hemoglobin Levels and Erythropoietin Doses in Hemodialysis and Peritoneal Dialysis Patients in the United States

Journal of the American Society of Nephrology

Volumn 15, Issue 1, 2004, Pages 174-179

  Snyder, Jon J ^a   Foley, Robert N ^a   Gilbertson, David T ^a   Vonesh, Edward F ^b   Collins, Allan J ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRIORITY JOURNAL; UNITED STATES;

EID: 0347994010     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000102475.94185.54     Document Type: Article

References (26)

1. Duke M, Abelmann WH: The hemodynamic response to chronic anemia. Circulation 39: 503-515, 1969
2. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13: 1642-1644, 1998
3. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997
4. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
5. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316, 1999
6. Collins AJ, Li S, Ebben J, Ma JZ, Manning W: Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36: 282-293, 2000
7. Collins AJ, Li S, St. Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473, 2001
8. Besarab A, Kline Bolton W, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit in patients with cardiac disease who are receiving hemodialysis and erythropoeitinetin. N Engl J Med 339: 584-590, 1998
9. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14: 1182-1187, 1999
10. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
11. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30[Suppl 3]: S192-S240, 1997
12. Levin NW, Lazarus JM, Nissenson AR: National Cooperative rHu Erythropoietin Study in patients with chronic renal failure - An interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis 22[Suppl 1]: 3-12, 1993
13. Besarab A, Golper TA: Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 37: M395-M396, 1991
14. Raja R, Bloom E, Johnson R: Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients. Adv Perit Dial 9: 177-180, 1993
15. Pais MJ, Gaspar A, Santana A, Bruges M, Simoes J. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Perit Dial Int 13[Suppl 2]: S541-S543, 1993
16. Conlon PJ, Walshe JJ, O'Donnell R, O'Donohoe A, Spencer R, Donohoe J, Carmody M: The use of recombinant human erythropoietin in end stage renal disease. Ir J Med Sci 162: 17-19, 1993
17. Raja R, Bloom E, Goldstein M, Johnson R: Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population. ASAIO J 39: M578-M580, 1993
18. Stegmayr BG: Better response to s. c. erythropoietin in CAPD than HD patients. Scand J Urol Nephrol 31: 183-187, 1997
19. Sieniawska M, Roszkowska-Blaim M: Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Pediatr Nephrol 11: 628-630, 1997
20. House AA, Pham B, Page DE: Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 13: 1763-1769, 1998
21. Centers for Medicare & Medicaid Services: Medicare & you 2003. Available at: www.medicare.gov/publications/pubs/pdt7 10050.pdf. Accessed January 31, 2003
22. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous erythropoeitinetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339: 578-583, 1998
23. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous erythropoeitinetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40: 439-446, 2002
24. Beckman BS, Brookins JW, Shadduck RK, Mangan KF, Deftos LJ, Fisher JW: Effect of different modes of dialysis on serum erythropoietin levels in pediatric patients. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2: 436-441, 1988
25. Flanigan MJ, Rocco MV, Prowant B, Frederick PR, Frankenfield DL: Clinical performance measures: The changing status of peritoneal dialysis. Kidney Int 60: 2377-2384, 2001
26. U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002, p 84